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incidence
The crude incidence of Hodgkin’s lymphoma (HL) in the
European Union is 2.3 and the mortality is 0.4 cases/100 000/
year. Young adults aged 20–40 years are most often affected;
however, a second incidence peak is seen in individuals aged 55
and older. Slightly more men than women are diagnosed with
HL. Histologically, classical HL (cHL) accounting for ∼95%
of all HL cases is distinguished from nodular lymphocyte-
predominant HL (NLPHL) representing ∼5% of all HL cases.
diagnosis
Pathological diagnosis should be made according to the World
Health Organization (WHO) classification from a sufficiently large
surgical specimen or excisional lymph node biopsy to provide
enough material for fresh frozen and formalin-fixed samples.
In cHL, the presence of Hodgkin and Reed–Sternberg (HRS)
cells is disease-defining while the detection of lymphocyte
predominant (LP) cells is required for the diagnosis of NLPHL.
The immunophenotype of the malignant cells in cHL and
NLPHL differs significantly. In contrast to HRS cells that stain
consistently positive for CD30 and CD15, occasionally positive
for CD20 and negative for CD45, LP cells are characterised by the
expression of CD20 and CD45 but they lack CD15 and CD30.
staging and risk assessment
The diagnostic work-up is shown in Table 1. The medical
history including the presence of B symptoms (fever, drenching
night sweats, unexplained weight loss >10% of total body weight
over 6 months) and other disease-related symptoms such as
fatigue, pruritus and alcohol-induced pain, as well as the results
of a physical examination, should be recorded [1].
Chest X-ray and a contrast-enhanced computed tomography
(CT) scan of neck, chest and abdomen are mandatory. In add-
ition, a baseline positron emission tomography (PET) should be
carried out according to the recommendations for staging and
response assessment in lymphoma whenever this diagnostic tool
is available [1, 2].
Given the high sensitivity of PET/CT for bone marrow involve-
ment, a bone marrow biopsy is no longer indicated in patients
undergoing PET/CT evaluation [III, B] [1–3]. However, bone
marrow biopsy must be carried out if PET/CT is not available.
Full blood cell count, erythrocyte sedimentation rate (ESR)
and blood chemistry including C-reactive protein, alkaline
phosphatase, lactate dehydrogenase, liver enzymes and albumin
are obligatory. Screening for hepatitis B, hepatitis C and human
immunodeficiency virus (HIV) is compulsory [II–III, A].
Staging is carried out according to the Ann Arbor classification
in consideration of defined clinical risk factors. After completion
of staging, patients are allocated to three categories (limited, inter-
mediate and advanced stages). Table 2 illustrates the European
Organisation for Research and Treatment of Cancer/Lymphoma
Study Association and the German Hodgkin Study Group defini-
tions of limited, intermediate and advanced stages [II–III, A].
To identify patients at increased risk for acute and/or long-
term complications, cardiac and pulmonary function tests
should be carried out before the start of treatment.
Since chemotherapy and radiotherapy (RT) can potentially
cause permanent fertility damage, reproductive counselling
must be offered to young patients of both genders before
treatment.
treatment of cHL
limited-stage patients
Combined modality treatment consisting of a brief chemother-
apy followed by RT was shown to result in superior tumour
control compared with RT alone [I, A] [4, 5] (Figure 1).
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Currently, two or three cycles of adriamycin/bleomycin/vin-
blastine/dacarbazine (ABVD) (Table 3) followed by involved-
field RT (IFRT) is considered standard of care for limited-stage
HL. A large multicentre trial in which patients were randomly
assigned to either two or four cycles of ABVD followed by either
20 or 30 Gy IFRT showed similar freedom from treatment
failure (FFTF) and overall survival (OS) rates for all treatment
groups. Thus, the least toxic approach consisting of two cycles
of ABVD followed by 20 Gy IFRT appears to be sufficient for
limited-stage HL [I, A] [6]. However, the current RT guidelines
of the International Lymphoma Radiation Oncology Group
(ILROG) recommend involved-site RT (ISRT) after chemother-
apy in limited stages although this recent strategy has not yet
been validated in a prospective study [7].
The question of whether RT can be omitted in patients with
complete metabolic response at interim PET is currently a
matter of debate and cannot be fully answered to date. Several
randomised trials addressing this issue have been initiated in
recent years. Emerging data consistently demonstrate a progres-
sion-free survival advantage also for patients with a complete
metabolic response at interim PET when treatment with com-
bined modality approaches is applied. A population that can be
safely treated with chemotherapy alone could not yet be defined
[8, 9]. Therefore, interim PET-guided treatment in limited-stage
HL is not recommended outside clinical studies.
intermediate-stage patients
Intermediate-stage HL is usually treated with combined modal-
ity approaches.
Four cycles of ABVD followed by 30 Gy IFRT is widely consid-
ered standard for intermediate-stage HL [I, A] [5]. In patients
≤60 years who are eligible for a more intensive treatment, this
standard is challenged by a protocol consisting of two cycles of
bleomycin/etoposide/adriamycin/cyclophosphamide/vincristine/
procarbazine/prednisone in escalated dose (BEACOPPescalated)
(Table 4) followed by two cycles of ABVD and 30 Gy IFRT.
After a median follow-up of 43 months, FFTF with this protocol
was superior in comparison with four cycles of ABVD followed
by 30 Gy IFRT. An advantage in OS could not be shown [I, B–C]
[10]. Although no results of a prospective study addressing this
issue are available to date, the ILROG guidelines recommend
ISRT instead of IFRT after chemotherapy in intermediate
stages [7].
The question of whether RT is dispensable in intermediate-
stage patients with complete metabolic response at interim PET
is unanswered. Trials addressing this issue are ongoing.
advanced-stage patients
Advanced-stage HL is usually treated with chemotherapy alone.
Additional RT is confined to patients with residual disease after
chemotherapy.
Table 1. Diagnostic work-up in Hodgkin’s lymphoma
Diagnosis
Lymph node biopsy (or a biopsy from another organ with
suspected affection)
Staging and risk stratification
Medical history and physical examination
X-ray of the chest
Contrast-enhanced CT scan of neck, chest and abdomen
PET
Full blood cell count and blood chemistry
HBV, HCV and HIV screening
Pre-treatment examinations
ECG
Echocardiography
Pulmonary function test
Reproductive counselling (in younger patients)
Serum pregnancy test (in younger female patients)
CT, computed tomography; PET, positron emission tomography;
HBV, hepatitis B; HCV, hepatitis C; HIV, human immunodeficiency
virus; ECG, electrocardiography.
Table 2. Definition of Hodgkin’s lymphoma risk groups according to the European Organisation for Research and Treatment of Cancer /Lymphoma
Study Association and the German Hodgkin Study Group
Treatment group EORTC/LYSA GHSG
Limited stages CS I–II without risk factors (supra-diaphragmatic) CS I–II without risk factors
Intermediate stages CS I–II with ≥1 risk factors (supra-diaphragmatic) CS I, CS IIA with ≥1 risk factors;
CS IIB with risk factors C/D, but not A/B
Advanced stages CS III–IV CS IIB with risk factors A/B, CS III/IV
Risk factors (A) Large mediastinal mass (A) Large mediastinal mass
(B) Age ≥50 years (B) Extranodal disease
(C) Elevated ESR (C) Elevated ESR
(D) ≥4 nodal areas (D) ≥3 nodal areas
Elevated ESR: >50 mm/h without B symptoms, >30 mm/h with B symptoms.
Large mediastinal mass: more than one-third of the maximum horizontal chest diameter.
B symptoms: fever, night sweat, unexplained weight loss >10% over 6 months.
EORTC: European Organisation for Research and Treatment of Cancer; LYSA: Lymphoma Study Association; GHSG: German Hodgkin Study Group;
CS: clinical stage; ESR: erythrocyte sedimentation rate.
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Patients ≤60 years are treated with either six to eight cycles of
ABVD followed by localised RT of residual lymphoma larger
than 1.5 cm or six cycles of BEACOPPescalated followed by loca-
lised RT of PET-positive residual lymphoma larger than 2.5 cm
[I, A] [11, 12]. Several trials randomly comparing ABVD and
BEACOPPescalated have shown a superior tumour control with
BEACOPPescalated [13–15]. A recent network meta-analysis in-
cluding 9993 patients also indicated a significantly better OS with
BEACOPPescalated when compared with ABVD. The survival
advantage was 10% at 5 years [16]. However, given the relevant
acute toxicity of BEACOPPescalated, appropriate surveillance and
supportive care must be available when this protocol is used. In
patients >60 years, the BEACOPP regimen should not be given,
as an increased rate of treatment-related mortality has been
observed in this age group [II, A] [17]. Thus, ABVD represents
the standard regimen for older HL patients who are fit enough
for treatment with multi-agent chemotherapy.
Retrospective analyses have indicated that early interim
PET might be a good predictor for treatment failure in patients
with advanced HL receiving ABVD chemotherapy [18, 19].
Therefore, ongoing trials aim at guiding treatment on the basis of
early interim PET which is used to distinguish between patients
who can potentially be cured with reduced therapy and patients
who require standard or even more intensive treatment. However,
given a lack of mature prospective data, treatment stratification
on the basis of early interim PET cannot be considered standard
as yet and further evidence from randomised trials is necessary.
Diagnosis of HL
Limited stages Intermediate stages Advanced stages
2 or 3 cycles of
ABVD
4 cycles of ABVD
or
2 cycles of BEACOPPesc +
2 cycles of ABVD
(£60 years)
6 to 8 cycles of ABVD
or
6 cycles of BEACOPPesc
(£60 years)
20 Gy IFRT
or
ISRT
30 Gy IFRT
or
ISRT
Localised RT to residual
lymphoma >1.5 cm
(after ABVD)
or
Localised RT to PET-positive
residual lymphoma >2.5 cm
(after BEACOPPesc)
Follow-up
Figure 1. Therapeutic algorithm for newly diagnosed Hodgkin’s lymphoma. HL, Hodgkin’s lymphoma; RT, radiotherapy; ABVD, adriamycin, bleomycin, vin-
blastine, dacarbazine; BEACOPPesc, bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone escalated dose regimen; ISRT,
involved-site radiotherapy; PET, positron emission tomography; NLPHL, nodular lymphocyte-predominant Hodgkin’s lymphoma; IFRT, involved-field RT.
Table 3. The adriamycin, bleomycin, vinblastine, dacarbazine
(ABVD) regimen
Adriamycin 25 mg/m2 i.v. Days 1 + 15
Bleomycin 10 mg/m2 i.v. Days 1 + 15
Vinblastine 6 mg/m2 i.v. Days 1 + 15
Dacarbazine 375 mg/m2 i.v. Days 1 + 15
Recycle: day 29.
Table 4. The bleomycin/etoposide/adriamycin/cyclophosphamide/
vincristine/ procarbazine/ prednisone in escalated dose
(BEACOPPescalated) regimen
Bleomycin 10 mg/m2 i.v. Day 8
Etoposide 200 mg/m2 i.v. Days 1–3
Adriamycin 35 mg/m2 i.v. Day 1
Cyclophosphamide 1250 mg/m2 i.v. Day 1
Vincristine 1.4 mg/m2
(maximum: 2 mg)
i.v. Day 8
Procarbazine 100 mg/m2 p.o. Days 1–7
Prednisone 40 mg/m2 p.o. Days 1–14
G-CSF s.c. From day 8
Recycle: day 22.
G-CSF, granulocyte colony-stimulating factor.
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relapsed disease
For most patients with refractory or relapsed HL, the treatment
of choice consists of high-dose chemotherapy followed by au-
tologous stem cell transplantation (ASCT) [II, A] [20, 21].
High-risk patients may benefit from tandem ASCT [III, B] [22].
Salvage regimens such as dexamethasone/high-dose Ara-C/
cisplatin (DHAP), ifosfamide/gemcitabine/vinorelbine (IGEV)
or ifosfamide/carboplatin/etoposide (ICE) are given to reduce
the tumour burden and mobilise stem cells before high-dose
chemotherapy and ASCT [II–III, A] [23–25].
A subset of low-risk patients relapsing after primary treat-
ment with two cycles of chemotherapy followed by RT can be
successfully salvaged with a second, more intensive convention-
al chemotherapy such as BEACOPPescalated [IV, B–C] [26].
In some patients with localised late relapse, salvage RT alone
appears to be sufficient [IV, B–C] [27].
The use of the antibody-drug conjugate brentuximab vedotin
represents an option in patients failing ASCT. After a pivotal
phase II study including 102 HL patients with relapse after ASCT
had revealed an overall response rate (ORR) of 75% with single-
agent brentuximab vedotin, the drug was recently approved for
the treatment of such patients [III, B] [28]. Alternatively, patients
can be enrolled in clinical trials evaluating novel agents.
Reduced-intensity conditioning allogeneic stem cell trans-
plantation (RIC-aSCT) can be considered in young, chemo-
sensitive patients in good general condition who relapse after
high-dose chemotherapy and ASCT [III, C] [29]. However,
RIC-aSCT is not a standard approach in HL and should be con-
ducted within clinical trials whenever possible.
In patients with multiple relapses who have no other treat-
ment options, acceptable remission rates, satisfying quality of
life and prolonged survival can be achieved by palliative single-
agent chemotherapy with gemcitabine or bendamustine and/or
regional RT [30, 31]. As brentuximab vedotin has also been
approved for the treatment of HL patients with disease recur-
rence after at least two lines of treatment who are not candidates
for high-dose chemotherapy followed by ASCT, its use can also
be considered in this patient group.
treatment of NLPHL
stage IAwithout risk factors
30 Gy IFRT alone is the standard treatment for stage IA NLPHL
patients without risk factors [III, A] [32].
other stages
Usually, NLPHL is treated identically to cHL in all stages except
for stage IA without risk factors [33]. As the malignant LP cells
of NLPHL consistently express CD20, addition of an anti-CD20
antibody may improve treatment efficacy [V, C]. However,
prospective data on this issue are not yet available.
relapsed NLPHL patients
Even more importantly than in cHL, a renewed biopsy should
be obtained in patients with suspected NLPHL relapse before
salvage therapy is initiated, since transformation into aggressive
non-Hodgkin’s lymphoma must be excluded. According to
newer analyses, transformation rates appear to be substantially
higher than previously reported [IV, A] [34, 35].
Localised NLPHL relapses can be effectively treated with
rituximab alone [III, B] [36].
Patients with more advanced disease at relapse often require a
more aggressive salvage therapy possibly combined with an
anti-CD20 antibody. However, prospective data on the use of
high-dose chemotherapy followed by ASCT are not available
yet.
Given the lack of CD30 on the malignant LP cells in NLPHL,
brentuximab vedotin does not represent a treatment option in
this entity.
response evaluation
Interim response evaluation by contrast-enhanced CT should be
carried out after completion of chemotherapy/before RT in limited
and intermediate stages and after four cycles of chemotherapy as
well as before RT in advanced stages. Retrospective studies includ-
ing advanced-stage and relapsed patients, respectively, have shown
that interim PET appears to be a useful tool to identify poor-risk
individuals [18, 19, 37]. However, interim PET-guided treatment
cannot be considered standard and should be restricted to clinical
trials except for the decision of whether patients with advanced
HL receiving BEACOPPescalated require RT [12].
Final staging should be carried out after completion of treat-
ment. Physical examination, laboratory analyses and contrast-
enhanced CT are mandatory. In addition, PET should be
carried out at final staging according to the guidelines for
staging and response assessment in lymphoma whenever this
diagnostic tool is available [1, 2].
prognosis
With modern treatment strategies, 80%–90% of HL patients
achieve permanent remission and can be considered cured.
personalised medicine
In HL, personalised treatment based on certain genetic features
as known for some malignancies is not established.
Treatment intensity is chosen according to the clinical stage
and the presence or absence of clinical risk factors (as described
in the staging and risk assessment section). The use of risk-
adapted therapy has led to excellent cure rates in HL patients ir-
respective of the stage at diagnosis.
Prospective studies evaluating interim PET-guided strategies
have been initiated, with the aim to discriminate between low-
risk patients who may be sufficiently treated with reduced-inten-
sity approaches and high-risk patients who require standard or
even intensified treatment. In patients with limited and inter-
mediate stages, the goal is to define a group of patients with
complete metabolic response after chemotherapy not requiring
consolidating RT. In advanced HL, it has been shown that RT is
dispensable in patients without PET-positive residual lymph-
oma larger than 2.5 cm after BEACOPPescalated chemotherapy.
Ongoing trials in advanced HL evaluate whether it is possible to
modify the intensity of chemotherapy based on the result of
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early interim PET. However, no mature data addressing this
issue are available to date.
follow-up
History, physical examination and laboratory analysis including
full blood cell count, ESR and blood chemistry should be carried
out every three months for the first half year, every 6 months
until the fourth year and once per year thereafter [V, B].
Additional evaluation of thyroid function (thyroid-stimulat-
ing hormone) after irradiation of the neck at one, two and at
least five years is recommended. Furthermore, testosterone and
oestrogen levels should be monitored, particularly in younger
patients who had intensive chemotherapy.
CT scans and previously pathologic radiographic tests must
be carried out once to confirm the remission status. Thereafter,
surveillance scans are not indicated unless clinical symptoms
occur [IV, B] [1, 2].
Patients should be asked for symptoms indicating the exist-
ence of long-term toxicity, particularly of heart and lung.
Cancer screening should be conducted regularly due to the
increased risk of haematological and solid secondary malignan-
cies after HL treatment.
note
A summary of recommendations is provided in Table 5. Levels
of evidence and grades of recommendation have been applied
using the system shown in Table 6. Statements without grading
were considered justified standard clinical practice by the
experts and the ESMO faculty.
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